WO2002069972A3 - Composes triazoliques et leur utilisation pour la prophylaxie et le traitement de maladies neurodegeneratives, de traumatismes cerebraux et d'ischemies cerebrales - Google Patents

Composes triazoliques et leur utilisation pour la prophylaxie et le traitement de maladies neurodegeneratives, de traumatismes cerebraux et d'ischemies cerebrales Download PDF

Info

Publication number
WO2002069972A3
WO2002069972A3 PCT/EP2002/002202 EP0202202W WO02069972A3 WO 2002069972 A3 WO2002069972 A3 WO 2002069972A3 EP 0202202 W EP0202202 W EP 0202202W WO 02069972 A3 WO02069972 A3 WO 02069972A3
Authority
WO
WIPO (PCT)
Prior art keywords
cerebral
prophylaxis
therapy
neurodegenerative diseases
triazole compounds
Prior art date
Application number
PCT/EP2002/002202
Other languages
German (de)
English (en)
Other versions
WO2002069972A2 (fr
Inventor
Gerd Steiner
Dorothea Starck
Kurt Schellhaas
Laszlo Szabo
Berthold Behl
Francisco Javier Garcia-Ladona
Liliane Unger
Original Assignee
Abbott Gmbh & Co Kg
Gerd Steiner
Dorothea Starck
Kurt Schellhaas
Laszlo Szabo
Berthold Behl
Francisco Javier Garcia-Ladona
Liliane Unger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg, Gerd Steiner, Dorothea Starck, Kurt Schellhaas, Laszlo Szabo, Berthold Behl, Francisco Javier Garcia-Ladona, Liliane Unger filed Critical Abbott Gmbh & Co Kg
Priority to AU2002251054A priority Critical patent/AU2002251054A1/en
Publication of WO2002069972A2 publication Critical patent/WO2002069972A2/fr
Publication of WO2002069972A3 publication Critical patent/WO2002069972A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés triazoliques et leur utilisation pour la prophylaxie et le traitement de maladies neurodégénératives, de traumatismes cérébraux et d'ischémies cérébrales, en particulier d'apoplexie cérébrale et de séquelles provoquées par ces maladies.
PCT/EP2002/002202 2001-03-01 2002-02-28 Composes triazoliques et leur utilisation pour la prophylaxie et le traitement de maladies neurodegeneratives, de traumatismes cerebraux et d'ischemies cerebrales WO2002069972A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002251054A AU2002251054A1 (en) 2001-03-01 2002-02-28 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10109866.9 2001-03-01
DE10109866A DE10109866A1 (de) 2001-03-01 2001-03-01 Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie

Publications (2)

Publication Number Publication Date
WO2002069972A2 WO2002069972A2 (fr) 2002-09-12
WO2002069972A3 true WO2002069972A3 (fr) 2002-12-19

Family

ID=7675936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002202 WO2002069972A2 (fr) 2001-03-01 2002-02-28 Composes triazoliques et leur utilisation pour la prophylaxie et le traitement de maladies neurodegeneratives, de traumatismes cerebraux et d'ischemies cerebrales

Country Status (3)

Country Link
AU (1) AU2002251054A1 (fr)
DE (1) DE10109866A1 (fr)
WO (1) WO2002069972A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037286A1 (fr) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Utilisation de derives de pteridine pour le traitement de l'augmentation de la pression intracranienne et de l'ischemie secondaire
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
BRPI0807219A2 (pt) 2007-02-08 2015-05-26 Synta Pharmaceuticals Corp Composto de tiazol que modulam a atividade de hsp90

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345948A2 (fr) * 1988-05-06 1989-12-13 SMITHKLINE BEECHAM PHARMA GmbH Utilisation de 5-HT1A agonistes pour l'obtention d'un médicament protégeant contre les conséquences d'une attaque ischémique
WO1996002520A1 (fr) * 1994-07-15 1996-02-01 Basf Aktiengesellschaft Composes triazole et leur utilisation comme ligands de la dopamine-d¿3?
WO1996004287A1 (fr) * 1994-07-29 1996-02-15 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a
WO1997025324A1 (fr) * 1996-01-12 1997-07-17 Basf Aktiengesellschaft Composes aza- et diazacycloheptane et -cyclo-octane substitues et leur utilisation
WO1999002503A1 (fr) * 1997-07-07 1999-01-21 Basf Aktiengesellschaft Composes de triazole et leur utilisation comme ligands de la dopamine d¿3?
WO2000067847A2 (fr) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Utilisation de ligands du recepteur de la dopamine d3 pour la production de medicaments servant au traitement de dysfonctionnements renaux
WO2001072306A1 (fr) * 2000-03-27 2001-10-04 Basf Aktiengesellschaft Utilisation de ligands du recepteur d3 de la dopamine pour traiter des maladies du systeme nerveux central

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345948A2 (fr) * 1988-05-06 1989-12-13 SMITHKLINE BEECHAM PHARMA GmbH Utilisation de 5-HT1A agonistes pour l'obtention d'un médicament protégeant contre les conséquences d'une attaque ischémique
WO1996002520A1 (fr) * 1994-07-15 1996-02-01 Basf Aktiengesellschaft Composes triazole et leur utilisation comme ligands de la dopamine-d¿3?
WO1996004287A1 (fr) * 1994-07-29 1996-02-15 Laboratorios Del Dr. Esteve, S.A. Tetrahydropyridine-(ou 4-hydroxypiperidine) alkylazoles ayant une activite pour les recepteurs sigma et/ou 5ht1a
WO1997025324A1 (fr) * 1996-01-12 1997-07-17 Basf Aktiengesellschaft Composes aza- et diazacycloheptane et -cyclo-octane substitues et leur utilisation
WO1999002503A1 (fr) * 1997-07-07 1999-01-21 Basf Aktiengesellschaft Composes de triazole et leur utilisation comme ligands de la dopamine d¿3?
WO2000067847A2 (fr) * 1999-05-07 2000-11-16 Basf Aktiengesellschaft Utilisation de ligands du recepteur de la dopamine d3 pour la production de medicaments servant au traitement de dysfonctionnements renaux
WO2001072306A1 (fr) * 2000-03-27 2001-10-04 Basf Aktiengesellschaft Utilisation de ligands du recepteur d3 de la dopamine pour traiter des maladies du systeme nerveux central

Also Published As

Publication number Publication date
DE10109866A1 (de) 2002-09-05
AU2002251054A1 (en) 2002-09-19
WO2002069972A2 (fr) 2002-09-12

Similar Documents

Publication Publication Date Title
WO2003000187A3 (fr) Nouvelles pyrazolo-pyrimidines et pyrrolo-pyrimidines et leur utilisation
CA2523831A1 (fr) 5,7-diaminopyrazolo[4,3]d!pyrimidines utiles pour le traitement de l'hypertension
ZA200306806B (en) Preparation for the prophylaxis of restenosis.
CA2458067A1 (fr) Utilisation de la flibanserine dans le traitement de troubles sexuels
ZA200306886B (en) Pyrazolopyrimidines as therapeutic agents.
WO2002064594A3 (fr) Pyrido-pyrimidines substituees en position 6
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
CA2460939A1 (fr) Composes de pyrazolyl substitues pour le traitement de l'inflammation
WO2007002361A3 (fr) Antagonistes du canal calcique de type t 3-fluoro-piperidine
WO2006110298A3 (fr) Nouveaux composes
GB0111186D0 (en) Novel compounds
MXPA03011546A (es) Formulacion farmaceutica.
CA2461567A1 (fr) Composes substitues de sulfamide benzene de pyrazolyl destines au traitement des inflammations
WO2003002064A3 (fr) Composes heterocycliques tenant lieu d'inhibiteurs selectifs de dhfr bacterienne, et utilisations
WO2006089664A3 (fr) Imidazoles substitues par heterocyclylamide
WO2004108062A3 (fr) Prophylaxie et/ou therapie de l'hypertonie portale
WO2003045324A3 (fr) 14-methyl-epothilones
WO2002069972A3 (fr) Composes triazoliques et leur utilisation pour la prophylaxie et le traitement de maladies neurodegeneratives, de traumatismes cerebraux et d'ischemies cerebrales
WO2002069946A3 (fr) Utilisation de composes de triazol pour la prophylaxie et la therapie de maladies neurodegeneratives, du traumatisme cerebral et de l'ischemie cerebrale
WO2002060483A3 (fr) Perylenequinones utilisees comme photosensibilisants et sonosensibilisants
AU2002362505A1 (en) Compression sleeve for treatment of the extremities
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
AU2003258983A1 (en) Combinations for the treatment of fungal infections
WO2003000269A3 (fr) Nouvelle utilisation d'inhibiteurs de pde 10a

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP